Related Experiment Video
Updated: May 4, 2026

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
Targeting GPR119 for the potential treatment of type 2 diabetes mellitus
Xiu-Lei Mo1, Zhao Yang1, Ya-Xiong Tao1
1Department of Anatomy, Physiology and Pharmacology, College of Veterinary Medicine, Auburn University, Auburn, Alabama, USA.
Abstract:
G protein-coupled receptor 119 (GPR119) was initially identified as an orphan receptor through mining the human genome database. In 2005, GPR119 was deorphanized and shown to be a receptor for fatty acid metabolites, including some phospholipids and fatty acid amide derivatives. GPR119 regulates various physiological processes that improve glucose homeostasis, including glucose-dependent insulin secretion from pancreatic β-cells, gastrointestinal incretin hormone secretion, appetite control, epithelial electrolyte homeostasis, gastric emptying, and β-cell proliferation and cytoprotection. Therefore, GPR119, the sensing receptor for fatty acid metabolites, represents a novel drug target for the treatment of type 2 diabetes mellitus.
More Related Videos
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
G Protein-coupled Receptors
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Diabetes Mellitus: Type 2 and Gestational
Dipeptidyl Peptidase 4 Inhibitors
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:

